Oligomerix to Present its drug discovery programme targeting tau oligomers

Oligomerix will be presenting its lead drug development programme during both the 9th Federation of European Neuroscience Societies (FENS) Forum of Neuroscience to be held 5–9 July 2014, in Milan, Italy and at the Alzheimer's Association International Conference (AAIC) to be held 12–17 July, 2014 in Copenhagen, Denmark.

The posters will highlight recent cell and animal studies showing that a compound selected by Oligomerix's proprietary technology platform can reduce pathological tau aggregates. These findings, which showed that the small molecules selected inhibited tau aggregation in mice, validate the company's approach for drug development.

 Oligomerix welcomes these opportunities to meet with pharmaceutical companies to advance its goal of forming strategic partnerships. 

9th FENS Forum of Neuroscience: Sunday, July 6, 2014:

Title:Alzheimer's disease drug development targeting tau oligomer formation

Authors:Giulia Papiani, Patricia Lopez, James Hendrix, Pavan Krishnamurthy, Daisy Romero, Eliot Davidowitz, & James Moe

Poster:C012

Location:Exhibition Hall: MioCo Conference Center (12:15 PM – 1:15 PM UTC)

AAIC 2014: Wednesday, July 16, 2014:

Title:Drug development of inhibitors of tau oligomer formation for Alzheimer's disease and tauopathies

Authors:James Moe, Pavan Krishnamurthy, Patricia Lopez, Giulia Papiani, Daisy Romero, James Hendrix, & Eliot Davidowitz

Poster:P4-212

Location:Bella Center A/S, Center Blvd. 5, DK-2300 Copenhagen S (11:45 AM - 2:15 PM UTC)